S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
3 ETFs for the Conservative Investor to Buy and Hold
Is Gold Really Boring? (Ad)
Are These Consumer Staples Too Cheap for Investors To Ignore?
Stock market today: Wall Street poised for more losses after Fed says rates may stay high in '24
Is Gold Really Boring? (Ad)
A small venture capital player becomes a symbol in the fight over corporate diversity policies
3 Reasons This Tech Giant Is Going Back To Highs
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Markets Are Loving These Stocks 'Firing On All Cylinders'
'Enough Venom to Fill a Martini Glass and Kill 5 People': An Amazon Driver Was Bitten By a Rattlesnake on the Job in Florida
NASDAQ:FGEN

FibroGen (FGEN) Stock Forecast, Price & News

$0.87
+0.08 (+10.07%)
(As of 09/20/2023 ET)
Compare
Today's Range
$0.78
$0.92
50-Day Range
$0.79
$2.67
52-Week Range
$0.70
$25.69
Volume
5.32 million shs
Average Volume
6.00 million shs
Market Capitalization
$85.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

FibroGen MarketRank™ Forecast

Analyst Rating
Reduce
1.67 Rating Score
Upside/​Downside
2,415.4% Upside
$22.00 Price Target
Short Interest
Healthy
11.91% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$29,599 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.47) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

254th out of 962 stocks

Pharmaceutical Preparations Industry

113th out of 452 stocks


FGEN stock logo

About FibroGen (NASDAQ:FGEN) Stock

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

FGEN Price History

FGEN Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
FibroGen stock plummets as muscular dystrophy drug trial fails
Stocks to Watch: FibroGen, Box
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
FibroGen Reports Second Quarter 2023 Financial Results
Expert Ratings for FibroGen
FibroGen Q2 2023 Earnings Preview
San FranciscoBusiness Times
FibroGen, Inc.: FibroGen Announces Leadership Transition
FibroGen Announces Leadership Transition
See More Headlines
Receive FGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for FibroGen and its competitors with MarketBeat's FREE daily newsletter.

FGEN Company Calendar

Last Earnings
8/07/2023
Today
9/21/2023
Next Earnings (Estimated)
11/06/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FGEN
Employees
592
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+2,415.4%
Consensus Rating
Reduce
Rating Score (0-4)
1.67
Research Coverage
6 Analysts

Profitability

Net Income
$-293,650,000.00
Net Margins
-246.75%
Pretax Margin
-248.26%

Debt

Sales & Book Value

Annual Sales
$140.73 million
Book Value
($0.02) per share

Miscellaneous

Free Float
95,863,000
Market Cap
$85.89 million
Optionable
Optionable
Beta
0.55

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Thane  WettigMr. Thane Wettig (Age 58)
    Interim Chief Exec. Officer
    Comp: $807.35k
  • Mr. Juan Graham (Age 46)
    Sr. VP & CFO
    Comp: $991.76k
  • Dr. Elias Kouchakji (Age 67)
    Sr. VP of Clinical Devel., Drug Safety & Pharmacovigilance
  • Ms. Christine L. Chung (Age 55)
    Sr. VP of China Operations
    Comp: $1.27M
  • Dr. Mark Eisner M.D. (Age 56)
    M.P.H., Exec. VP & Chief Medical Officer
    Comp: $992.95k
  • Dr. Barry A. Berkowitz Ph.D.
    Founder
  • Dr. John J. Hunter Ph.D. (Age 60)
    Chief Scientific Officer
  • Ms. Karen L. Bergman
    VP of Investor Relations & Corp. Communications
  • Mr. Michael D. Lowenstein J.D.
    Ph.D., Chief Legal Officer
  • Ms. Tricia Stewart
    Chief People Officer













FGEN Stock - Frequently Asked Questions

Should I buy or sell FibroGen stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for FibroGen in the last year. There are currently 2 sell ratings and 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" FGEN shares.
View FGEN analyst ratings
or view top-rated stocks.

What is FibroGen's stock price forecast for 2023?

6 brokerages have issued 1 year price targets for FibroGen's stock. Their FGEN share price forecasts range from $2.00 to $35.00. On average, they predict the company's stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 2,415.4% from the stock's current price.
View analysts price targets for FGEN
or view top-rated stocks among Wall Street analysts.

How have FGEN shares performed in 2023?

FibroGen's stock was trading at $16.02 at the beginning of 2023. Since then, FGEN shares have decreased by 94.5% and is now trading at $0.8746.
View the best growth stocks for 2023 here
.

Are investors shorting FibroGen?

FibroGen saw a decline in short interest during the month of August. As of August 31st, there was short interest totaling 10,810,000 shares, a decline of 5.7% from the August 15th total of 11,460,000 shares. Based on an average trading volume of 3,950,000 shares, the short-interest ratio is currently 2.7 days. Currently, 11.9% of the company's shares are short sold.
View FibroGen's Short Interest
.

When is FibroGen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our FGEN earnings forecast
.

How were FibroGen's earnings last quarter?

FibroGen, Inc. (NASDAQ:FGEN) announced its earnings results on Monday, August, 7th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.07. The biopharmaceutical company earned $44.32 million during the quarter, compared to analysts' expectations of $34.17 million. FibroGen had a negative trailing twelve-month return on equity of 879.75% and a negative net margin of 246.75%.

What other stocks do shareholders of FibroGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other FibroGen investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Aegean Marine Petroleum Network (ANW), NIC (EGOV), Gran Tierra Energy (GTE), Allergan (AGN) and ALJ Regional (ALJJ).

When did FibroGen IPO?

(FGEN) raised $146 million in an initial public offering on Friday, November 14th 2014. The company issued 8,100,000 shares at a price of $18.00 per share. Goldman Sachs, Citigroup and Leerink Partners acted as the underwriters for the IPO and RBC Capital Markets, Stifel and William Blair were co-managers.

What is FibroGen's stock symbol?

FibroGen trades on the NASDAQ under the ticker symbol "FGEN."

Who are FibroGen's major shareholders?

FibroGen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (5.11%), Schroder Investment Management Group (3.42%), Geode Capital Management LLC (1.90%), Assenagon Asset Management S.A. (1.52%), Affinity Asset Advisors LLC (0.00%) and Goldman Sachs Group Inc. (0.90%). Insiders that own company stock include Benjamin Cravatt, Christine Chung, Enrique A Conterno, James A Schoeneck, Jeffrey William Henderson, Juan Graham, K Peony Yu, Kalevi Kurkijarvi, Mark Eisner, Pat Cotroneo, Thane Wettig and Thomas F Kearns Jr.
View institutional ownership trends
.

How do I buy shares of FibroGen?

Shares of FGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is FibroGen's stock price today?

One share of FGEN stock can currently be purchased for approximately $0.87.

How much money does FibroGen make?

FibroGen (NASDAQ:FGEN) has a market capitalization of $85.89 million and generates $140.73 million in revenue each year. The biopharmaceutical company earns $-293,650,000.00 in net income (profit) each year or ($3.39) on an earnings per share basis.

How many employees does FibroGen have?

The company employs 592 workers across the globe.

How can I contact FibroGen?

FibroGen's mailing address is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. The official website for the company is www.fibrogen.com. The biopharmaceutical company can be reached via phone at (415) 978-1200, via email at ir@fibrogen.com, or via fax at 415-978-1902.

This page (NASDAQ:FGEN) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -